



Cite this: *Org. Biomol. Chem.*, 2015, **13**, 8067

Received 9th March 2015,  
Accepted 25th June 2015

DOI: 10.1039/c5ob00465a

www.rsc.org/obc

## Functionalising the azobenzene motif delivers a light-responsive membrane-interactive compound with the potential for photodynamic therapy applications†

Theodore J. Hester,<sup>a</sup> Sarah R. Dennison,<sup>b</sup> Matthew J. Baker<sup>c</sup> and Timothy J. Snape<sup>\*b</sup>

When adorned with *n*-octyl chains azobenzene is able to disrupt a variety of calcein-loaded phospholipid liposomes. The levels of lysis observed are dependent both on the lipid headgroup and the conformation of the azobenzene compound. In all cases studied, it has been shown that the *cis*-conformer is more membrane-interactive than the *trans*-conformer, suggesting that this class of molecule could be optimised for photo-dynamic therapy applications against infectious pathogens.

### Introduction

The use of light for the photoisomerisation of azobenzene (**1**, Scheme 1) and its derivatives has been exploited in numerous biomedical applications.<sup>1</sup> For example, light as a trigger has been used to induce changes in a molecular assembly for the controlled release of chemical compounds;<sup>2</sup> to drive functional changes in peptides, proteins, nucleic acids, lipids, and carbohydrates;<sup>3</sup> and for the *in vivo* light-activation of ion channels for the remote control of neuronal firing which has potential applications in controlling activity downstream from sites of neural damage or degeneration.<sup>4</sup> Moreover, proteasome inhibitors, widely used as cytotoxic agents in cancer treatment, have been prepared through the introduction of a photoswitchable azobenzene motif into the molecular structures studied, giving rise to chemotherapeutic agents that can be switched on and off with light.<sup>5</sup>


The precedent for azobenzene derivatives to be exploited as light-triggered molecular switches in biological systems suggested that such a practice might be combined with our current interests studying the nature of non-covalent interactions between conformationally distinct benzanilides (*e.g.* **2**) and diarylureas with phospholipid monolayers,<sup>6–9</sup> if suitable changes to the azobenzene motif could be incorporated, as a

way of designing new photodynamic therapeutic agents for infectious diseases.

### Results and discussion

Scheme 1 outlines the approach taken to merge the desired structural features of **1** and **2** and the subsequent synthesis of the target compound (**4**, 73%) using a TEMPO/CuBr-based oxidative coupling of 4-*n*-octylaniline (**3**).<sup>10</sup> With suitable quantities of the lipophilic azobenzene derivative **4** in hand, attempts to determine its spectroscopic and conformational properties were undertaken, prior to studying the interaction of any isolable conformers with phospholipid membranes.

To determine the response of **4** to UV light, a 0.125 mM stock solution was prepared in a suitable solvent or water: solvent mix and spectra recorded every 10 s using 365 nm irradiation (ESI†). In the absence of UV irradiation, an intense  $\pi$ - $\pi^*$  transition band at around 330 nm and a weaker  $n$ - $\pi^*$  transition band around 440 nm is observed for *trans*-**4**.<sup>3</sup>



**Scheme 1** Azobenzene (**1**), a lipid-interactive benzanilide (**2**) and the conformationally similar azobenzene derivatives studied here (**4** and **5**), and their synthesis.

<sup>a</sup>School of Forensic and Investigative Sciences, University of Central Lancashire, Preston, PR1 2HE, UK

<sup>b</sup>School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, PR1 2HE, UK. E-mail: tjsnape@uclan.ac.uk; Tel: +44 (0)1772 895805

<sup>c</sup>WestCHEM, Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow, G1 1XL, UK. E-mail: matthew.baker@strath.ac.uk;

Tel: +44 (0)141 548 4700

† Electronic supplementary information (ESI) available: Synthesis, characterisation, UV and membrane lysis experiments. See DOI: 10.1039/c5ob00465a



Following irradiation of **4** with 365 nm light for 180 s a spectrum indicative of *cis*-**5** was recorded which possessed a  $n-\pi^*$  transition with a higher intensity compared to the *trans*-isomer.<sup>3</sup> Despite this difference, a photostationary equilibrium is set up meaning that a maximum of ~85% of the *cis*-isomer forms upon irradiation at 330 nm, an observation that was confirmed by <sup>1</sup>H NMR (see below).

To ensure that the observed conformational change was fully reversible, a relaxation experiment was carried out, as above, using a 532 nm laser as the light source and the now “excited” sample of **5** (0.125 mM solution). In this case, after irradiation with the 532 nm laser using 30 s intervals for 10 min, an identical time-course spectral series was recorded to that of the original *trans*-sample (**4**), indicating that the *n*-octyl-functionalised azobenzene (**4**) was able to switch conformations, as anticipated.<sup>11</sup>

Corroboration of the light-induced conformational switch was achieved when the experiment was repeated in CDCl<sub>3</sub> and the irradiated sample analysed directly by NMR and compared to the non-irradiated sample. Similar changes in the UV spectra to those seen with the other solvents above were obtained in CDCl<sub>3</sub>. The changes in the <sup>1</sup>H NMR of **4** were compared prior to irradiation, after 21 h of 365 nm irradiation, and after exposure of the irradiated sample to darkness and heat or 532 nm light (to promote relaxation back to *trans*-**4**). The spectra (ESI<sup>†</sup>) show an expected upfield shift occurs upon irradiation of *trans*-**4**,<sup>12</sup> giving a spectrum which is consistent with the *cis*-conformation (**5**). Similarly, a switch back to the *trans*-conformer (**4**) occurs with 532 nm light or at 60 °C in the dark. In all spectra a small amount of the other conformer is visible, consistent with the UV experiments above. Combined, these results support that a conformational switch occurs between *trans*-**4** and *cis*-**5**, whereby it switches from *trans* to *cis* at 365 nm and switches back again at 532 nm (or 60 °C in the dark).

Having confirmed that the azobenzene derivative **4** cleanly undergoes the expected conformational switch, and that its relaxation back to the *trans*-conformer is sufficiently slow (>21 h) to enable assays to take place on the individual conformers, attention turned to establish what, if any, interactions the two conformers have with phospholipid membranes. Moreover, if the two conformers were able to interact with phospholipid membranes, it could be determined whether the results mirror those of the benzanilide conformers of **2** studied previously,<sup>6,8</sup> whereby the *cis*-conformer was shown to be more membrane interactive than the *trans*-conformer, presumably a consequence of both lipid chains inserting into, and disrupting the membrane, rather than predominantly only one of the *trans*-compound.<sup>6,8</sup> Furthermore, the light-switching advantage of the azobenzene series over the *N*-methylation state “pseudo-switch” of the amide series means that the compounds could be optimised for photodynamic therapy applications, especially for topical treatments.

A concentration-dependent calcein-release assay was used to determine the extent to which the two conformers are able to lyse liposomes loaded with the fluorescent dye.<sup>13</sup> Four inde-

pendent single-lipid liposomes were used which were composed of dimyristoyl phosphatidylethanolamine (DMPE), dimyristoyl phosphatidylglycerol (DMPG), dimyristoyl phosphatidylserine (DMPS) and dimyristoyl phosphatidylcholine (DMPC), phospholipids which are the main constituents in, and can therefore act as simple membrane mimics of, *Escherichia coli* (DMPE) and *Staphylococcus aureus* (DMPG)<sup>14</sup> or cancer cells (DMPS and DMPC).<sup>15</sup> The total lipid concentration used in the assay was 100 μM, with a P/L ratio ranging from ~1 : 4 (24 μM) to ~1 : 33 (3 μM).

The results (Fig. 1) demonstrate that the compounds do interact with phospholipid membranes, and that there is a significant difference between the two conformers, with *cis*-**5** being more membrane-interactive than *trans*-**4** across all lipids tested, results which mimic the trend of the benzanilide analogue too.<sup>6,8</sup>

The maximal lysis observed occurred with *cis*-**5** and liposomes consisting of DMPS, where a plateau was reached at 12 μM (~64% lysis) in 1 h, a value that was not superseded even at double that concentration. These results compare well to those of *cis*- and *trans*-benzanilide (**2**)<sup>6</sup> against DMPE and DMPG liposomes where, even at the higher concentration of 400 μM, the maximum levels of lysis were 25.0 ± 0.3% and 42.9 ± 0.1% for the *trans*- and *cis*-conformers respectively against liposomes composed of DMPE lipid, and 21.1 ± 0.6% and 41.9 ± 0.2% for the *trans*- and *cis*-conformers respectively against liposomes composed of DMPG lipid. These can be compared to the data shown in Fig. 1 (at 12 μM) of 10.41 ± 0.30% and 33.44 ± 0.22% for *trans*-**4** and *cis*-**5** respectively against liposomes composed of DMPE lipid, and 28.58 ±




Fig. 1 The ability of *trans*-**4** (top) and *cis*-**5** (bottom) to induce membrane leakage using the lipids DMPE (solid black line), DMPG (solid dark grey line), DMPS (solid light grey line) and DMPC (dotted black line). The data shown are the average of three independent experiments.



0.21% and  $54.72 \pm 0.31\%$  for *trans*-4 and *cis*-5 respectively against liposomes composed of DMPG lipid, suggesting that, in both cases, the *cis*-conformer is the most active form at lysing liposomes. Presumably such a trend occurs because in the *cis*-conformation the lipid chains are able to insert into the lipid bilayer and disrupt the membrane packing. Since conversion of the isomers at or near the membrane is the core concept here, the behaviour of the isomers in the presence of lipids was ascertained (ESI†). A simple UV-Vis experiment was performed in which a spectral series of the azobenzene derivatives were followed over time in the presence of the liposomes made up from both DMPC and DMPE, and it was shown that identical series were obtained, in each case, to those of the series in the absence of the lipids, suggesting that the azobenzene derivatives are able to switch their conformations in the presence of lipids, as required. Since compounds 2, 4 and 5 contain the same lipid side-chains, the differences observed between the compounds and different liposomes studied is therefore seemingly dependent on the specific interactions between the phosphate headgroups and the motif linking the two adorned benzene rings. Although it is known that hydrophobic molecules can disrupt phospholipid membranes, there is a significant difference between *trans*-4 and *cis*-5 suggesting that shape plays an important role here too.

As can be seen in Fig. 2, the size of the two conformers varies such that the distance between the *para*-positions of the benzene rings (the location of the alkyl chains) is smallest in the *cis*-isomer ( $\sim 0.5$  nm *cf.*  $\sim 1.0$  nm). This geometry means that in the *cis*-conformation, the *n*-octyl chains are better positioned to interact with, and disrupt, the membrane packing (Fig. 2, left – shown for clarity with one molecule, although in reality clustering of the compounds in the membrane would most likely occur). Combined with the larger dipole moment of the *cis*-isomer enabling larger ion-dipole interactions to take place between 5 and the negatively charged membrane, makes the *cis*-isomer more membrane disruptive than the *trans*.

Whether studying the azobenzene derivative here, benzanilides,<sup>6,8</sup> ureas,<sup>7</sup> or other constructs,<sup>16,17</sup> the subtle differences in the non-covalent interactions experienced between the particular molecular motif and the lipid headgroup should affect the stability of the compound in the membrane, and hence the level of lysis observed.<sup>18–24</sup> For example, the membrane's charge varies depending the nature of the phosphate head-


group (*i.e.* ethanolamine, glycerol, serine and choline in DMPE, DMPG, DMPS and DMPC, respectively), as does the exact make-up of the charge, *i.e.* whether is it net neutral (zwitterionic) as seen in DMPE and DMPC, negative as seen in DMPG, or net negative (zwitterionic) as seen in DMPS, and this makes a difference in the levels to which the membrane is lysed.<sup>18,19</sup>

Such findings demonstrate that the properties of the lipid polar headgroup are important in such systems and the overall amount of lysis is governed by a fine balance of interaction contributions.


Having observed that the *cis*-conformer is more membrane-interactive than *trans*-4 over a 1 h time period, we were interested in understanding what would happen over an extended time period of 24 h. This could be important since this is the sort of time-scale in which a *cis*  $\rightarrow$  *trans* relaxation may begin to take place, and thus if it did whilst the compound was buried in the membrane, it would further increase the levels of membrane lysis observed, and its potential as a membrane-disruptive compound.

Again, a concentration-dependent time course was studied against all four lipids (ESI†), but representative data can be seen in Fig. 3 at 12  $\mu$ M for simplicity.

As seen in Fig. 3, against all lipids the *cis*-conformer (5) is more membrane lytic than *trans*-4, sometimes as much as two-fold or more, and in most cases, maximal lysis occurs, and a plateau is reached, around the 3 h time-point. Overall maximal lysis occurs at  $\sim 80\%$  for *cis*-5 against DMPS, but interestingly,



**Fig. 2** (a) A schematic showing the proposed mechanism for membrane disruption of *cis*-5 (left, shown, for clarity with one molecule), and (b) the reversible isomerisation of azobenzene showing its geometry and dipole changes (right).



**Fig. 3** The kinetics of calcein release over time after addition of 12  $\mu$ M (P/L =  $\sim 1:8$ ) *trans*-4 (top) and *cis*-5 (bottom) to 100  $\mu$ M DMPE (solid black line), DMPG (dark grey line), DMPC (dotted black line) and DMPS (light grey line). After 7 hours the sample ceased calcein release and this did not change over time.



there appears to be very little, if any, selectivity for liposomes composed of DMPC between the two conformers. If the difference between the levels of lysis caused by the *cis* and *trans* conformers for each time point are calculated, then it can be seen that, for all cases except the 1 h time-point, both the neutral (zwitterionic) lipids DMPE and DMPC have the smallest difference in lysis for the two conformers. This is in contrast to the two negatively charged lipids DMPG and DMPS, which have the greatest difference, and more specifically, the negative (zwitterionic) lipid DMPS is the most lysed liposome of all those studied. This difference provides a handle with which to potentially prepare compounds which can be photochemically switched to selectively interact with different phospholipid membranes, and thus be optimised to be selective chemotherapeutic agents.

Evidently, these subtle differences in phospholipid headgroups are able to impart small selectivities in the interaction of **4** and **5** with the different liposomes. However, the time-point of the plateaus (~3 h) are not long enough to induce a *cis* → *trans* transition under ambient conditions, and so we propose that the increased membrane lysis in the case of *cis*-**5** is due to this conformer being able to better interact with the membrane than *trans*-**4** (Fig. 1) and not due to isomerisation whilst embedded in the membrane, or hydrophobic effects alone.

## Conclusions

In conclusion, we have shown that an azobenzene motif adorned with suitable *n*-octyl chains is able to disrupt a variety of independent calcein-loaded liposomes composed of four different phospholipids, and that the levels of lysis observed are dependent both on the lipid headgroup and the conformation of the molecules being studied. In all cases, it has been shown that the *cis*-conformer is more membrane-interactive than the corresponding *trans*-conformer, results which mimic those of other structurally-related conformational switches,<sup>6,8</sup> suggesting that this class of molecule could be optimised for photo-dynamic therapy applications.

Future work will look to focus on studying mixed lipid systems and further adorning the benzene rings with water-solubilising groups, groups which could also shift the wavelength of light required to implement the conformational switch to the visible spectrum,<sup>1</sup> as well as introducing charge to the molecules to increase their interaction with net negative membranes, as has seen success recently with pyridinium analogues.<sup>9</sup>

## Acknowledgements

The authors would like to thank the EPSRC UK National Mass Spectrometry Facility (NMSF), Swansea.

## Notes and references

- 1 A. A. Beharry, O. Sadovski and G. A. Woolley, *J. Am. Chem. Soc.*, 2011, **133**, 19684–19687.
- 2 X. Wang, S. Werner, T. Weiss, K. Liefeth and C. Hoffmann, *RSC Adv.*, 2012, **2**, 156–160.
- 3 A. A. Beharry and G. A. Woolley, *Chem. Soc. Rev.*, 2011, **40**, 4422–4437.
- 4 M. Banghart, K. Borges, E. Isacoff, D. Trauner and R. H. Kramer, *Nat. Neurosci.*, 2004, **7**, 1381–1386.
- 5 M. J. Hansen, W. A. Velema, G. de Bruin, H. S. Overkleeft, W. Szymanski and B. L. Feringa, *ChemBioChem*, 2014, **15**, 2053–2057.
- 6 S. R. Dennison, Z. Akbar, D. A. Phoenix and T. J. Snape, *Soft Matter*, 2012, **8**, 3258–3264.
- 7 S. R. Dennison, D. A. Phoenix and T. J. Snape, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 2518–2521.
- 8 S. R. Dennison, T. J. Snape and D. A. Phoenix, *Eur. Biophys. J.*, 2012, **41**, 687–693.
- 9 S. Fahs, F. B. Rowther, S. R. Dennison, Y. Patil-Sen, T. Warr and T. J. Snape, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 3430–3433.
- 10 Z. Hu and F. M. Kerton, *Org. Biomol. Chem.*, 2012, **10**, 1618–1624.
- 11 S. Moeller, U. Pliquet and C. Hoffmann, *RSC Adv.*, 2012, **2**, 4792–4801.
- 12 K. M. Tait, J. A. Parkinson, A. C. Jones, W. J. Ebenezer and S. P. Bates, *Chem. Phys. Lett.*, 2003, **374**, 372–380.
- 13 T. M. Allen and L. G. Cleland, *Biochim. Biophys. Acta*, 1980, **597**, 418–426.
- 14 K. Lohner and E. J. Prenner, *Biochim. Biophys. Acta*, 1999, **1462**, 141–156.
- 15 T. Utsugi, A. J. Schroit, J. Connor, C. D. Bucana and I. J. Fidler, *Cancer Res.*, 1991, **51**, 3062–3066.
- 16 A. D. Bautista, C. J. Craig, E. A. Harker and A. Schepartz, *Curr. Opin. Chem. Biol.*, 2007, **11**, 685–692.
- 17 A. Som, S. Vemparala, I. Ivanov and G. N. Tew, *Biopolymers*, 2008, **90**, 83–93.
- 18 A. A. Stromstedt, P. Wessman, L. Ringstad, K. Edwards and M. Malmsten, *J. Colloid Interface Sci.*, 2007, **311**, 59–69.
- 19 T. Le Bihan, D. Pelletier, P. Tancrede, B. Heppell, J. P. Chauvet and C. R. Gicquaud, *J. Colloid Interface Sci.*, 2005, **288**, 88–96.
- 20 R. M. Epand, *Biochim. Biophys. Acta*, 1998, **1376**, 353–368.
- 21 R. M. Epand and R. F. Epand, *Biochim. Biophys. Acta*, 2009, **1788**, 289–294.
- 22 R. M. Epand and R. F. Epand, *J. Pept. Sci.*, 2011, **17**, 298–305.
- 23 B. P. Mowery, S. E. Lee, D. A. Kissounko, R. F. Epand, R. M. Epand, B. Weisblum, S. S. Stahl and S. H. Gellman, *J. Am. Chem. Soc.*, 2007, **129**, 15474–15476.
- 24 D. Koller and K. Lohner, *Biochim. Biophys. Acta*, 2014, **1838**, 2250–2259.

